miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments

Autor:	Luz Tonatzin Orozco Moreno, Oliver Millan Catalan, Antonio Daniel Martinez‑Gutierrez, Fany Iris Porras Reyes, Rafael Vázquez‑Romo, Alma D. Campos‑Parra, Juan Enrique Bargallo Rocha, Carlos Pérez Plasencia, Luis A. Herrera, Alberto Alvarado Miranda, Fernando Lara Medina, David Cantú de León, César López‑Camarillo
Rok vydání:	2019
Předmět:	0301 basic medicine Oncology Adult medicine.medical_specialty Breast Neoplasms Disease Metastasis 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Genetics Biomarkers Tumor Medicine Humans Neoplasm Metastasis Survival rate Aged Neoplasm Staging Oncogene business.industry Cancer High-Throughput Nucleotide Sequencing Reproducibility of Results General Medicine Articles Middle Aged medicine.disease Prognosis Metastatic breast cancer Molecular medicine Combined Modality Therapy Survival Analysis microRNAs Gene Expression Regulation Neoplastic 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Female next-generation sequencing metastatic breast cancer business Transcriptome
Zdroj:	International Journal of Molecular Medicine
ISSN:	1791-244X
Popis:	Metastatic breast cancer (MBC) is a challenge for oncologists, and public efforts should focus on identifying additional molecular markers and therapeutic management to improve clinical outcomes. Among all diagnosed cases of breast cancer (BC; approximately 10%) involve metastatic disease; notably, approximately 40% of patients with early‑stage BC develop metastasis within 5 years. The management of MBC consists of systemic therapy. Despite different treatment options, the 5‑year survival rate is
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::139c1011c6860ebb34ee85126d37338d https://pubmed.ncbi.nlm.nih.gov/31364724 Zobrazit plný text záznamu